// App-Quantinova.ai

: Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study

Researchers

Presenter

  • Joseph M. Connors

Principal Investigators

  • Anas Younes

  • Andrea Gallamini

  • Stephen M. Ansell

  • Won-Seog Kim

  • Ranjana H Advani

  • Nancy L. Bartlett

  • David J. Straus

  • Anna Sureda

  • Martin Hutchings

  • Monika Dlugosz-Danecka

  • Gerald Engley

  • Keenan Fenton

  • Rachael Liu

  • Harry Miao

  • Hina Jolin

  • Ashish Gautam

  • John Radford

Medical Centers

  • British Columbia Cancer Agency Center for Lymphoid Cancer, Vancouver, BC, Canada

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Research Innovation and Statistics, Antoine-Lacassagne Cancer Centre, Nice, France

  • Mayo Clinic, Rochester, MN

  • Samsung Medical Center, seoul, CA, Korea, Republic of (South)

  • Stanford University Cancer Institute, Stanford, CA

  • Alvin J Siteman Cancer Center at Washington University School of Medicine, St. Louis, MO

  • Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Institut Catala d Oncologia, Hospital Duran i Reynals, Barcelona, Spain

  • Department of Hematology, Rigshospitalet, Copenhagen, Denmark

  • Department of Hematology, Jagiellonian University Hospital, Krakow, Poland

  • Seattle Genetics, Bothell, WA

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Takeda Oncology, Cambridge, MA.

  • The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

Locations

  • Canada

  • United States

  • France

  • Republic of South Korea

  • Spain

  • Denmark

  • Poland

  • United Kingdom

Companies

  • Seattle Genetics, In

  • Millennium Pharmaceu

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Adcetris

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01712490

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved